Sharyl Attkisson on the MSM War on HCL for the China Virus, and the FDA's Response

By A Buddy
Wed, May 20, 2020 4:57 p.m.

Sharyl Attkisson: press war on HCL [10m], FDA backs down; doctors can now prescribe HCL beyond hospitals

A bit off topic but in it's own way related:

The same follow-the-money principle that drives immigration policy also drives therapeutic drug availability:

1) Attkinsson (May 17) interviews three medical experts on the press attack on HCL and then applies the follow-the-money principle to FDA decision-making as regards availability of HCL beyond hospitals (all in less than 10 minutes).

Below that: Just yesterday (May 19) the FDA has backed down on guidance limiting HCL to hospitals. They must have been under enormous pressure:

“HYDROXYCHLOROQUINE” WITH SHARYL ATTKISSON (May 17th 2020, Video and Transcript: 9m40s)
http://fullmeasure.news/news/cover-story/hydroxychloroquine

Summary: Sharyl Attkisson interviews:

Dr. William O’Neill (2m10 in) [cardiologist, director, Henry Ford Health System]: “President Trump touted it early, so the media set out to discredit it, without any regard for science.”

Dr. Steven Hatfill (4m45s in) [biomedical scientist who worked on Ebola, studies pandemic responses in medicine]: “Why are the press running medicine in the United States? . . . Lives were lost [because of the attack on HCL].”

Dr. Jane Orient, executive director, Association of American Physicians and Surgeons (6m in):

“The ones [physicians] with the most experience are very enthusiastic about the possibilities [of HCL] . . . I think you have to look at the money. There’s no big profits made in hydroxychloroquine. It’s very cheap, easy to manufacture, been around for 70 years. It’s generic . . . So I think we really do have to consider there’s some financial interest involved here.”

==========

2) MAY 19: FDA BACKS OFF GUIDANCE LIMITING HCL TO HOSPITALS: “FDA appears to soften stance on hydroxychloroquine after Trump says he takes malaria drug,” CNBC:
https://www.cnbc.com/amp/2020/05/19/fda-appears-to-soften-stance-on-hydroxychloroquine-after-trump-says-he-takes-malaria-drug.html

KEY QUOTE: “The U.S. Food and Drug Administration said Tuesday that taking hydroxychloroquine is ‘ultimately’ a choice between patients and their health-care providers, appearing to soften its earlier advisory against taking the anti-malaria drug outside of a hospital.

"‘The decision to take any drug is ultimately a decision between a patient and their doctor,’ FDA Commissioner Dr. Stephen Hahn said in a statement to CNBC. ‘Hydroxychloroquine and chloroquine are already FDA-approved for treating malaria, lupus, and rheumatoid arthritis.’”

WHAT THE FDA WAS SAYING A MONTH AGO: “...in a warning issued last month, the FDA advised consumers against taking drugs chloroquine and hydroxychloroquine for Covid-19 outside a hospital or formal clinical trial due to the risk of ‘serious heart rhythm problems.’

"‘Hydroxychloroquine and chloroquine can cause abnormal heart rhythms such as QT interval prolongation and a dangerously rapid heart rate called ventricular tachycardia,’ the agency wrote in the notice. ‘We will continue to investigate risks associated with the use of hydroxychloroquine and chloroquine for COVID-19 and communicate publicly when we have more information.’"